Replies to post #1400 on Cytokinetics, Inc. (CYTK)

[H2R]

SoS: sales potential of $10 to $15 billion.

From SmithOnStock:

Results from the COSMIC HF phase 2 trial of omecamtiv mecarbil support the hypothesis that it improves heart function and (very importantly) reverses structural damage in patients with heart failure. Side effects are comparable to placebo.

If these results are replicated in the GALACTIC-HF phase 3 trial, I believe that omecamtiv mecarbil has peak annual sales potential of $10 to $15 billion.

Amgen and Cytokinetics announced that the Phase 3 GALACTIC HF trial has started.

It will enroll around 8000 patients.

Topline data could be available in mid-2021.